Skip to main content
Clinical Trials/NCT06456736
NCT06456736
Not yet recruiting
Not Applicable

Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment

Central South University0 sites200 target enrollmentJune 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autoimmune Encephalitis
Sponsor
Central South University
Enrollment
200
Primary Endpoint
Modified Rankin Scale
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

Autoimmune encephalitis (AE) is a potentially life-threatening inflammation of the central nervous system (CNS) and constitutes 20%-30% of encephalitis cases in adults AE often leads to subacute, severe, and debilitating encephalitis necessitating long-term management in a neurologic intensive care unit (ICU). This study aims to explore the predictive factors for poor clinical outcomes by analyzing the clinical characteristics and prognosis of adult patients with critical AE requiring ICU admission. Prospective observational single center study in neurologic ICU, the second Xiangya hospital, Central South University. All patients admitted to the ICU for probable or confirmed AE (2022 Chinese guidelines for diagnosis and treatment of AE) will be included. Factors associated with a poor prognosis will be identified by multivariate analysis using a logistic regression.

Registry
clinicaltrials.gov
Start Date
June 2024
End Date
August 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Central South University
Responsible Party
Principal Investigator
Principal Investigator

Lixia Qin

Principal Investigator

Central South University

Eligibility Criteria

Inclusion Criteria

  • Diagnosed as either ''definite'' or ''probable'' AE based on Chinese guidelines for diagnosis and treatment of AE (version 2022)
  • Age ≥ 15 years
  • Admission to an adult ICU during the course of the disease

Exclusion Criteria

  • Missing data on primary outcome
  • ICU length of stay of 24 hours or less.

Outcomes

Primary Outcomes

Modified Rankin Scale

Time Frame: 12 months

The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It has become the most widely used clinic. mRS is scored on a scale of 0 to 6. The higher the score, the worse the prognosis

Secondary Outcomes

  • Mortality(12 months)
  • Rate of complications(12 months)

Similar Trials